Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients
Lack of vision improvement, amongst other efficacy concerns, as well as potential for conversion to neovascular age-related macular degeneration are among core barriers limiting Syfovre uptake, according to Spherix Global Insights. EXTON, Pa., June 28, 2023 –With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy […]
Nearly One Year Post-Launch Biogen & Coherus Biosciences’ Ranibizumab Biosimilars Have Yet to Make a Splash in Their Respective Retina Markets
Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to be cooling, according to a recent analysis from Spherix Global Insights. EXTON, Pa., June 23, 2023 — Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars Today and […]
Genentech’s Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, 2023 — Genentech’s Vabysmo got an 18-month head start over Regeneron’s high dose Eylea (8mg aflibercept), but that lead time may be coming to a […]
Roche’s Genentech debuts first consumer effort for diabetes and age-related eye disease drug
Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped screen, stepping through into different beach, gardening and hiking scenarios. The campaign theme “Open Up Your World” mirrors her narration that the eye medication can improve eyesight and “open up” favorite activities for people with […]
Genentech’s Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights
Despite a very satisfied Vabysmo user-base, Regeneron’s 8mg aflibercept is already highly anticipated by ophthalmologists and likely to throw a wrench into Vabysmo’s positive trajectory. EXTON, Pa., March 29, 2023 – According to Spherix Global Insights’ Launch Dynamix™: Vabysmo service, to no surprise, Regeneron’s Eylea continues to lead the charge in both the nAMD and […]
Apellis Ushers in a New Era of Geographic Atrophy Treatment with First Ever Approval, According to Spherix Global Insights
Spherix Global Insights surveyed 85 US ophthalmologists, revealing awareness of Apellis’s newly approved GA therapy, Syfovre is high, as are intentions to trial the agent Exton, PA., February 28, 2023 – Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is an advanced form of […]
Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences’ Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech’s Lucentis
According to a survey of ophthalmologists, in the first six months of biosimilar availability, aided awareness and familiarity are marginal while willingness to prescribe is low. Exton, PA., February 24, 2023 – Last summer, the introduction of biosimilar agents into ophthalmologists’ armamentarium was a big event in the United States medical community. Despite the availability […]
Retina Specialist: Why are ophthalmologists a definite maybe about biosimilars? Survey provides answers
February 14, 2023 Even with the launch of the first two anti-VEGF biosimilars last year, retina specialists seem somewhat ambivalent about using these copy-cat versions of tried and true treatments, a new report based on a survey of ophthalmologists has found. The report, titled “Special Topix: Ophthalmology Biosimilars Today and Tomorrow,” is based on a […]
Switching Patterns Among Diabetic Macular Edema: Regeneron’s Eylea Withstands the Evolving DME Switch Landscape
With the DME treatment landscape evolving, ophthalmologists have the opportunity to explore more novel approaches in hopes of easing treatment burden. But will they take the plunge and stray from the tried-and-true options? EXTON, Pa., February 13, 2023 – The patient switch territory is evolving as more agents become available. Spherix’s RealWorld Dynamix™ report allows […]
Ophthalmology Times: Impact of biosimilar availability on the US ophthalmology markets
Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report. A new Spherix Global Insights study reported the results of a survey of 80 ophthalmologists in the US that sought feedback on the use and perceptions of biosimilar agents and their impact […]
